EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Circulating microRNAs and Cardiomyocyte Proliferation in Heart Failure Patients Related to 10 Years Survival

Vilas Wagh, Filomain Nguemo, Zlata Kiseleva, Robert M Mader, Juergen Hescheler, Werner Mohl

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Vilas Wagh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Merck Research Labs, Boston, MA, USA. Hauptthemen laut MEDLINE: Circulating MicroRNA, MicroRNAs, Heart Failure. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Austrian Science Fund, Federal Ministry of Traffic, Innovation, and Technology, Society of Coronary Sinus Interventions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Mechanochemical signalling drives organogenesis and is highly conserved in mammal evolution. Regaining recovery in myocardial jeopardy by inducing principles linking cardiovascular therapy and clinical outcome has been the dream of scientists for decades. Concepts involving embryonic pathways to regenerate adult failing hearts became popular in the early millennium. Since then, abundant data on stem cell research have been published, never reaching widespread application in heart failure therapy. Another conceptual access, using mechanotransduction in cardiac veins to limit myocardial decay, is pressure-controlled intermittent coronary sinus occlusion (PICSO). Recently, we reported acute molecular signs and signals of PICSO activating regulatory miRNA and inducing cell proliferation mimicking cardiac development in adult failing hearts. According to a previously formulated hypothesis, ‘embryonic recall’, this study aimed to define molecular signals involved in endogenous heart repair during PICSO and study their relation to patient survival. Methods and results We previously reported a study on the acute molecular effects of PICSO in an observational non-randomized study. Eight out of the thirty-two patients with advanced heart failure undergoing cardiac resynchronization therapy (CRT) were treated with PICSO. Survival was monitored over 10 years, and coronary sinus blood samples were collected during intervention before and after 20 min and tested for miRNA signalling and proliferation when co-cultured with cardiomyocytes. A numerically lower death rate post-CRT and PICSO as compared with control CRT only, and a non-significant reduction in all-cause mortality risk of 42% was observed (37.5% vs. 54.0%, relative risk = 0.58, 95% confidence interval: 0.17–2.05; P = 0.402). Four miRNAs involved in cell cycle, proliferation, morphogenesis, embryonic development, and apoptosis significantly increased concomitantly in survivors and PICSO compared with a decrease in non-survivors (hsa-miR Let7b, P < 0.01; hsa-miR- 421, P < 0.006; hsa-miR 363-3p, P < 0.03 and hsa-miR 19b-3p P < 0.01). In contrast, three miRNAs involved in proliferation and survival, determining cell fate, and recycling endosomes decreased in survivors and PICSO (hsa miR 101-3p, P < 0.03; hsa-miR 25-3p, P < 002; hsa-miR 30d-5p P < 0.04). In vitro cellular proliferation increased in survivors and lowered in non-survivors showing a pattern distinction, discriminating longevity according to up to 10-year survival in heart failure patients.

Conclusions

This study proposes that generating regenerative signals observed during PICSO intervention relate to patient outcomes. Morphogenetic pathways induced by periods of flow reversal in cardiac veins in a domino-like pattern transform embryonic into regenerative signals. Studies supporting the conversion of mechanochemical signals into regenerative molecules during PICSO are warranted to substantiate predictive power on patient longevity, opening new therapeutic avenues in otherwise untreatable heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating MicroRNAMicroRNAsHeart FailureAdultAnimalsHumansMyocytes, CardiacMechanotransduction, CellularCell ProliferationMammals

Stichwörter der Autor:innen

Cardiac regenerationCirculating miRNAsEmbryonic recallHeart failurePICSO

Substanzen

Circulating MicroRNAMicroRNAsMIRN363 microRNA, human

Autor:innen und Institutionen

  • Merck Research Labs, Boston, MA, USA.
  • Center of Physiology and Pathophysiology, Institute of Neurophysiology, University of Cologne, Cologne, Germany.
  • Department of Cardiac Surgery emeritus, Medical University Vienna, Vienna, Austria.
  • Department of Medicine I, Medical University Vienna, Vienna, Austria.

Förderung

  • Austrian Science Fund
  • Federal Ministry of Traffic, Innovation, and Technology
  • Society of Coronary Sinus Interventions

Zitieren

APA

Wagh, V., Nguemo, F., Kiseleva, Z., Mader, R. M., Hescheler, J., & Mohl, W. (2023). Circulating microRNAs and Cardiomyocyte Proliferation in Heart Failure Patients Related to 10 Years Survival. ESC Heart Failure. https://doi.org/10.1002/ehf2.14516

Vancouver

Wagh V, Nguemo F, Kiseleva Z, Mader RM, Hescheler J, Mohl W. Circulating microRNAs and Cardiomyocyte Proliferation in Heart Failure Patients Related to 10 Years Survival. ESC Heart Failure. 2023. doi:10.1002/ehf2.14516

BibTeX
@article{Wagh2023,
  author = {Wagh, Vilas and Nguemo, Filomain and Kiseleva, Zlata and Mader, Robert M and Hescheler, Juergen and Mohl, Werner},
  title = {Circulating microRNAs and Cardiomyocyte Proliferation in Heart Failure Patients Related to 10 Years Survival},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14516}
}
Kostenlos starten →